AR107592A1 - Derivados de tetrahidroisoquinolina - Google Patents
Derivados de tetrahidroisoquinolinaInfo
- Publication number
- AR107592A1 AR107592A1 ARP170100336A ARP170100336A AR107592A1 AR 107592 A1 AR107592 A1 AR 107592A1 AR P170100336 A ARP170100336 A AR P170100336A AR P170100336 A ARP170100336 A AR P170100336A AR 107592 A1 AR107592 A1 AR 107592A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- halogen
- group
- substituents selected
- Prior art date
Links
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 22
- 229910052736 halogen Inorganic materials 0.000 abstract 17
- 150000002367 halogens Chemical class 0.000 abstract 11
- 125000001424 substituent group Chemical group 0.000 abstract 11
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 150000001721 carbon Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 abstract 2
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical group FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000002235 sarcomere Anatomy 0.000 abstract 2
- 125000001544 thienyl group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 206010049565 Muscle fatigue Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 102000004903 Troponin Human genes 0.000 abstract 1
- 108090001027 Troponin Proteins 0.000 abstract 1
- 102000013534 Troponin C Human genes 0.000 abstract 1
- 102000013394 Troponin I Human genes 0.000 abstract 1
- 108010065729 Troponin I Proteins 0.000 abstract 1
- 102000004987 Troponin T Human genes 0.000 abstract 1
- 108090001108 Troponin T Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 208000016334 muscle symptom Diseases 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 210000003903 pelvic floor Anatomy 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 210000005070 sphincter Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos de tetrahidroisoquinolina que pueden usarse como un ingrediente activo para una composición farmacéutica, y en particular, para una composición farmacéutica útil para prevenir o tratar una enfermedad o condición que responde a la modulación de la contractilidad del sarcómero esquelético. Esto puede lograrse, por ejemplo, por modulación del complejo de troponina del sarcómero de músculo esquelético rápido mediante una o más de miosina esquelética rápida, actina, tropomiosina, troponina C, troponina I, y troponina T, y fragmentos e isoformas de las mismas. Los compuestos derivados de tetrahidroisoquinolina pueden usarse entonces como agente para prevenir o tratar 1) trastornos neuromusculares, 2) trastornos de músculos voluntarios, 3) trastomos del SNC en los cuales la debilidad muscular, atrofia, y fatiga son síntomas prominentes, 4) síntomas musculares que derivan de trastornos sistémicos, y 5) disfunciones del piso pélvico y del músculo del esfinter uretral / anal. Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1), o una sal del mismo, donde, X¹: C-R¹¹ o N; X²: C-R¹² o N; R¹¹: i) H, ii) halógeno, iii) -CN, o iv) -O-C₁₋₆ alquilo; R¹²: H o halógeno; R¹: i) H, ii) C₁₋₆ alquilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno, y pirazolilo, iii) C₂₋₆ alquenilo, o iv) -OR⁰; R²: i) C₁₋₆ alquilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en -OR⁰, halógeno, -COOR⁰, -CONR²¹R²², fenilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo G¹, y heteroarilo que se selecciona entre el grupo que consiste en piridilo, pirazolilo, imidazolilo, tiazolilo, tiadiazolilo, tienilo, oxazolilo, isoxazolilo, y triazolilo, donde, el heteroarilo puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo G², ii) C₂₋₆ alquenilo, iii) C₂₋₆ alquinilo, iv) -OR⁰, v) -NR²³R²⁴, vi) -COOR⁰, o vii) fenilo; R²¹: H o C₁₋₆ alquilo; R²²: i) C₁₋₆ alquilo que puede estar sustituido con uno o más fenilo, o ii) fenilo; R²³: i) H, o ii) C₁₋₆ alquilo que puede estar sustituido con uno o más -OH; R²⁴: i) C₁₋₆ alquilo que puede estar sustituido con uno o más fenilo que puede estar sustituido con uno o más halógeno, ii) C₃₋₈ cicloalquilo que puede estar sustituido con uno o más C₁₋₆ alquilo, iii) fenilo que puede estar sustituido con uno o más halógeno, o iv) tetrahidropiranilo; o R¹, R², y un átomo de carbono unido a R¹ y R² pueden unirse para formar un anillo 4-piperidina o anillo 4-tetrahidropirano, y el átomo de carbono unido a R¹ y R² es un átomo espiro y el anillo 4-piperidina puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en -SO₂-(C₁₋₆ alquilo) y -COOR⁰; R³, R⁴: iguales o diferentes entre sí, i) C₁₋₃ alquilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en halógeno y -OH o ii) C₂₋₆ alquenilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en -OH y heteroarilo que se selecciona entre el grupo que consiste en pirazolilo y tienilo, donde el heteroarilo puede estar sustituido con uno o más C₁₋₆ alquilo, o, R³, R⁴, y un átomo de carbono unido a R³ y R⁴ pueden unirse para formar un anillo 3-oxetano y el átomo de carbono unido a R³ y R⁴ es un átomo espiro; R⁵: i) H, ii) C₁₋₆ alquilo que puede estar sustituido con uno o más -O-(C₁₋₆ alquilo), iii) -O-C₁₋₆ alquilo, iv) halógeno, v) -COO-(C₁₋₆ alquilo), o vi) C₃₋₈ cicloalquilo; R⁶: i) H, ii) C₁₋₆ alquilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en -O-(C₁₋₆ alquilo que puede estar sustituido con uno o más halógeno) y halógeno, iii) -OH, iv) -O-(C₁₋₆ alquilo que puede estar sustituido con uno o más halógeno), v) halógeno, vi) -CN, vii) -S-(C₁₋₆ alquilo), viii) C₃₋₈ cicloalquilo, ix) -NR⁰R⁰, o x) C₂₋₆ alquenilo; grupo G¹: i) halógeno, ii) -COOR⁰, iii) -CONR⁰R⁰, iv) -OH, v) C₁₋₆ alquilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en -OH y halógeno, o vi) -O-(C₁₋₆ alquilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en -OH y halógeno); grupo G²: i) halógeno, ii) C₁₋₆ alquilo que puede estar sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en -OH y halógeno o iii) -CONR⁰R⁰; R⁰: iguales o diferentes entre sí, H o C₁₋₆ alquilo; con la condición de que dicho compuesto no es 1,1-dialil-3-oxo-2,4-dihidroisoquinolin-4-carboxilato de metilo o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662285039P | 2016-02-12 | 2016-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107592A1 true AR107592A1 (es) | 2018-05-16 |
Family
ID=59561239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100336A AR107592A1 (es) | 2016-02-12 | 2017-02-10 | Derivados de tetrahidroisoquinolina |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9914741B2 (es) |
| EP (2) | EP4032877A1 (es) |
| JP (2) | JP6832943B2 (es) |
| KR (1) | KR20180120701A (es) |
| CN (2) | CN109069498B (es) |
| AR (1) | AR107592A1 (es) |
| AU (1) | AU2017217663B2 (es) |
| BR (1) | BR112018016475A2 (es) |
| CA (1) | CA3012839A1 (es) |
| CL (1) | CL2018002287A1 (es) |
| CO (1) | CO2018007920A2 (es) |
| CY (1) | CY1125222T1 (es) |
| DK (1) | DK3413892T3 (es) |
| ES (1) | ES2913423T3 (es) |
| HR (1) | HRP20220655T1 (es) |
| HU (1) | HUE058820T2 (es) |
| IL (1) | IL261055B (es) |
| LT (1) | LT3413892T (es) |
| MA (1) | MA44018B1 (es) |
| MD (1) | MD3413892T2 (es) |
| MX (1) | MX379159B (es) |
| NZ (1) | NZ746311A (es) |
| PH (1) | PH12018501694B1 (es) |
| PL (1) | PL3413892T3 (es) |
| PT (1) | PT3413892T (es) |
| RS (1) | RS63240B1 (es) |
| RU (1) | RU2743424C2 (es) |
| SG (1) | SG11201806416XA (es) |
| SI (1) | SI3413892T1 (es) |
| SM (1) | SMT202200201T1 (es) |
| TW (2) | TWI773118B (es) |
| UA (1) | UA124879C2 (es) |
| WO (1) | WO2017139526A1 (es) |
| ZA (1) | ZA201804947B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3413892T3 (da) | 2016-02-12 | 2022-05-23 | Cytokinetics Inc | Tetrahydroisoquinolinderivater |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| US11981644B2 (en) | 2020-11-06 | 2024-05-14 | Cytokinetics, Inc. | Bicyclic 1,4-diazepanones and therapeutic uses thereof |
| WO2025080100A1 (ko) * | 2023-10-11 | 2025-04-17 | 한국화학연구원 | 신규한 디-아미드 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN117379425A (zh) * | 2023-11-14 | 2024-01-12 | 广州日聚商贸发展有限公司 | 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3301857A (en) | 1963-08-26 | 1967-01-31 | Hoffmann La Roche | Spiro |
| SE368009B (es) | 1971-09-16 | 1974-06-17 | Kabi Ab | |
| PL331602A1 (en) | 1996-08-06 | 1999-08-02 | Pfizer | Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives |
| IL128994A (en) | 1996-09-25 | 2004-12-15 | Zeneca Ltd | History of quinoline and naphthyridine and their salts, processes for their preparation, pharmaceutical preparations containing them and their use as medicines |
| US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US6743599B1 (en) | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US7202051B1 (en) | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| WO2001007411A1 (en) * | 1999-07-26 | 2001-02-01 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| MXPA06012323A (es) | 2004-04-28 | 2007-01-17 | Takeda Pharmaceutical | Derivado de quinolina fusionada y uso del mismo. |
| JP2009524589A (ja) * | 2005-12-22 | 2009-07-02 | ワイス | 置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン誘導体、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用 |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| EP2583970B1 (en) | 2006-08-02 | 2015-10-14 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods comprising imidazopyrimidines |
| CN101595094B (zh) * | 2006-12-27 | 2013-02-20 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹诺酮衍生物 |
| EP2097400B1 (en) | 2007-01-05 | 2013-07-03 | Daiichi Sankyo Company, Limited | Fused substituted aminopyrrolidine derivative |
| TW200901991A (en) | 2007-05-25 | 2009-01-16 | Amgen Inc | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| WO2009108332A1 (en) * | 2008-02-27 | 2009-09-03 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 |
| CN101518971B (zh) * | 2008-02-29 | 2012-07-18 | E.I.内穆尔杜邦公司 | 聚酯叠层膜和使用该叠层膜的太阳能电池板 |
| WO2010038901A1 (en) * | 2008-10-02 | 2010-04-08 | Taisho Pharmaceutical Co., Ltd. | 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| KR20110099687A (ko) | 2008-10-29 | 2011-09-08 | 데시페라 파마슈티칼스, 엘엘씨. | 항-암과 항-증식성 활성을 나타내는 시클로프로판 아미드와 유사체 |
| WO2010131145A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| WO2011159760A1 (en) | 2010-06-16 | 2011-12-22 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| WO2012112946A1 (en) * | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| HUP1100241A3 (en) * | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
| JP6345645B2 (ja) | 2012-04-02 | 2018-06-20 | サイトキネティックス， インコーポレイテッド | 横隔膜機能を向上させるための方法 |
| SG10201704166RA (en) | 2012-04-11 | 2017-06-29 | Cytokinetics Inc | Improving resistance to skeletal muscle fatigue |
| AR091699A1 (es) * | 2012-07-10 | 2015-02-25 | Astellas Pharma Inc | Derivado de indol carboxamida |
| SMT202200096T1 (it) | 2014-04-29 | 2022-03-21 | Cytokinetics Inc | Metodi per ridurre il declino della capacità vitale |
| WO2016039367A1 (ja) | 2014-09-09 | 2016-03-17 | アステラス製薬株式会社 | 尿失禁予防用及び／又は治療用新規医薬組成物 |
| DK3413892T3 (da) * | 2016-02-12 | 2022-05-23 | Cytokinetics Inc | Tetrahydroisoquinolinderivater |
-
2017
- 2017-02-10 DK DK17750801.7T patent/DK3413892T3/da active
- 2017-02-10 MA MA44018A patent/MA44018B1/fr unknown
- 2017-02-10 SI SI201731142T patent/SI3413892T1/sl unknown
- 2017-02-10 HU HUE17750801A patent/HUE058820T2/hu unknown
- 2017-02-10 MX MX2018009759A patent/MX379159B/es unknown
- 2017-02-10 LT LTEPPCT/US2017/017295T patent/LT3413892T/lt unknown
- 2017-02-10 JP JP2018541693A patent/JP6832943B2/ja not_active Expired - Fee Related
- 2017-02-10 AU AU2017217663A patent/AU2017217663B2/en not_active Ceased
- 2017-02-10 KR KR1020187026486A patent/KR20180120701A/ko not_active Withdrawn
- 2017-02-10 CN CN201780010949.1A patent/CN109069498B/zh not_active Expired - Fee Related
- 2017-02-10 PH PH1/2018/501694A patent/PH12018501694B1/en unknown
- 2017-02-10 MD MDE20181214T patent/MD3413892T2/ro unknown
- 2017-02-10 ES ES17750801T patent/ES2913423T3/es active Active
- 2017-02-10 NZ NZ746311A patent/NZ746311A/en not_active IP Right Cessation
- 2017-02-10 CN CN202110837700.6A patent/CN113666938A/zh active Pending
- 2017-02-10 SG SG11201806416XA patent/SG11201806416XA/en unknown
- 2017-02-10 WO PCT/US2017/017295 patent/WO2017139526A1/en not_active Ceased
- 2017-02-10 AR ARP170100336A patent/AR107592A1/es unknown
- 2017-02-10 EP EP22160176.8A patent/EP4032877A1/en not_active Withdrawn
- 2017-02-10 CA CA3012839A patent/CA3012839A1/en active Pending
- 2017-02-10 HR HRP20220655TT patent/HRP20220655T1/hr unknown
- 2017-02-10 RU RU2018130002A patent/RU2743424C2/ru active
- 2017-02-10 TW TW110103986A patent/TWI773118B/zh not_active IP Right Cessation
- 2017-02-10 US US15/429,738 patent/US9914741B2/en active Active
- 2017-02-10 EP EP17750801.7A patent/EP3413892B1/en active Active
- 2017-02-10 TW TW106104493A patent/TWI719138B/zh not_active IP Right Cessation
- 2017-02-10 BR BR112018016475-5A patent/BR112018016475A2/en active Search and Examination
- 2017-02-10 PT PT177508017T patent/PT3413892T/pt unknown
- 2017-02-10 UA UAA201809258A patent/UA124879C2/uk unknown
- 2017-02-10 SM SM20220201T patent/SMT202200201T1/it unknown
- 2017-02-10 PL PL17750801T patent/PL3413892T3/pl unknown
- 2017-02-10 RS RS20220483A patent/RS63240B1/sr unknown
-
2018
- 2018-01-17 US US15/873,571 patent/US10259821B2/en active Active
- 2018-07-23 ZA ZA2018/04947A patent/ZA201804947B/en unknown
- 2018-07-30 CO CONC2018/0007920A patent/CO2018007920A2/es unknown
- 2018-08-08 IL IL261055A patent/IL261055B/en active IP Right Grant
- 2018-08-10 CL CL2018002287A patent/CL2018002287A1/es unknown
-
2019
- 2019-03-04 US US16/291,481 patent/US10689393B2/en active Active
-
2020
- 2020-05-11 US US16/871,532 patent/US11479561B2/en active Active
-
2021
- 2021-02-01 JP JP2021014223A patent/JP7137650B2/ja active Active
-
2022
- 2022-06-03 CY CY20221100392T patent/CY1125222T1/el unknown
- 2022-09-13 US US17/944,060 patent/US20230125280A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107592A1 (es) | Derivados de tetrahidroisoquinolina | |
| AR103546A1 (es) | Compuestos de bipiridina y su uso para controlar artrópodos dañinos | |
| AR124916A2 (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| JP2018516904A5 (es) | ||
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| EA201890641A3 (ru) | Стимуляторы sgc | |
| AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
| PE20171511A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| AR099489A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| AR094990A1 (es) | Derivados de amida y su uso para el tratamiento de infección por vih | |
| AR092670A1 (es) | Derivados de quinazolinona | |
| AR077066A1 (es) | Derivados de tiazolilpiperidina como fungicidas, procedimientos para su preparacion e intermediarios de sintesis utilizados en los mismos. | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| SG10201900144TA (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| PE20220806A1 (es) | Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b | |
| JOP20200191A1 (ar) | مشتقات أوكسادايازولو بيريدين بها استبدال بسيكليل غير متجانسة للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) | |
| AR110283A1 (es) | Dinucleótido cíclico | |
| AR117006A1 (es) | Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| WO2015172059A8 (en) | Pyrazole derivatives and their use as cannabinoid receptor mediators | |
| BR112015022084A2 (pt) | composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol | |
| AR104539A1 (es) | Compuestos cíclicos | |
| AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| AR093763A1 (es) | Antagonistas de ccr3 de arilsulfonamida isotopicamente enriquecidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |